A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.

Official Title

A Phase I/Ib, Open-label, Multi-centre, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.

Summary:

The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumour activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers

Trial Description

Primary Outcome:

  • Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178
Secondary Outcome:
  • Overall response rate (ORR)
  • Clinical Benefit Rate (CBR)
  • Progression Free Survival (PFS)
  • Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.
  • Plasma concentration vs. time profiles for NIR178 and derived PK parameters
  • To assess the immunogenicity of NZV930 and PDR001
  • Characterize changes in the immune infiltrate in tumours

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society